KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA (2016 - 2025)

Historic EBITDA for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $113.2 million.

  • Alnylam Pharmaceuticals' EBITDA rose 22115.03% to $113.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $292.5 million, marking a year-over-year increase of 20111.3%. This contributed to the annual value of $328.2 million for FY2025, which is 21343.52% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' EBITDA stood at $113.2 million, which was up 22115.03% from $259.3 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBITDA registered a high of $259.3 million during Q3 2025, and its lowest value of -$407.5 million during Q3 2022.
  • In the last 5 years, Alnylam Pharmaceuticals' EBITDA had a median value of -$148.7 million in 2023 and averaged -$120.0 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' EBITDA plummeted by 16672.98% in 2024, and later skyrocketed by 35477.94% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBITDA stood at -$257.5 million in 2021, then rose by 19.08% to -$208.4 million in 2022, then skyrocketed by 38.13% to -$128.9 million in 2023, then increased by 27.5% to -$93.5 million in 2024, then skyrocketed by 221.15% to $113.2 million in 2025.
  • Its EBITDA was $113.2 million in Q4 2025, compared to $259.3 million in Q3 2025 and -$58.7 million in Q2 2025.